- Home
- LIXT vs IMCC Comparison
LIXT vs IMCC Comparison
Compare LIXT & IMCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- IMCC
- Stock Information
- Founded
- LIXT 2005
- IMCC 1980
- Country
- LIXT United States
- IMCC Israel
- Employees
- LIXT N/A
- IMCC N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- IMCC Medicinal Chemicals and Botanical Products
- Sector
- LIXT Health Care
- IMCC Health Care
- Exchange
- LIXT Nasdaq
- IMCC Nasdaq
- Market Cap
- LIXT 12.4M
- IMCC 12.2M
- IPO Year
- LIXT N/A
- IMCC N/A
- Fundamental
- Price
- LIXT $4.47
- IMCC $2.05
- Analyst Decision
- LIXT
- IMCC
- Analyst Count
- LIXT 0
- IMCC 0
- Target Price
- LIXT N/A
- IMCC N/A
- AVG Volume (30 Days)
- LIXT 121.5K
- IMCC 38.5K
- Earning Date
- LIXT 08-07-2025
- IMCC 08-12-2025
- Dividend Yield
- LIXT N/A
- IMCC N/A
- EPS Growth
- LIXT N/A
- IMCC N/A
- EPS
- LIXT N/A
- IMCC N/A
- Revenue
- LIXT N/A
- IMCC $38,430,631.00
- Revenue This Year
- LIXT N/A
- IMCC $47.12
- Revenue Next Year
- LIXT N/A
- IMCC $12.83
- P/E Ratio
- LIXT N/A
- IMCC N/A
- Revenue Growth
- LIXT N/A
- IMCC 5.08
- 52 Week Low
- LIXT $0.64
- IMCC $1.29
- 52 Week High
- LIXT $5.14
- IMCC $7.12
- Technical
- Relative Strength Index (RSI)
- LIXT 58.29
- IMCC 36.41
- Support Level
- LIXT $3.20
- IMCC $1.90
- Resistance Level
- LIXT $4.60
- IMCC $2.48
- Average True Range (ATR)
- LIXT 0.51
- IMCC 0.24
- MACD
- LIXT 0.06
- IMCC -0.02
- Stochastic Oscillator
- LIXT 78.53
- IMCC 16.58
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.